What are the major differences in biomarker test adoption in European countries? An analysis of PD–L1 testing in Italy and Germany.

23rd February 2017 at 11am EST
Register

webinar-register

Listen again to our industry experts providing analysis and insight on what you need for successful development and commercialization of testing for targeted therapies.

 

Moving beyond the hype: the reality of NGS in oncology today and in the future

Jun 29, 2017 | Speakers: Jordan Clark, Peter Krein, Dr. Vincent Funari

Has NGS lived up to the hype of industry predictions?

Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and how will this affect future adoption and utility?

This collaborative discussion between Diaceutics and NeoGenomics Laboratories will shed light on the clincial and commercial reality of NGS in oncology with predictions for what lies ahead. To attend register below.


What are the major differences in biomarker test adoption in European countries? An analysis of PD–L1 testing in Italy and Germany

Feb 23, 2017 | Speakers: Jordan Clark, Luiz Corrêa

Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In this webinar, we will discuss the adoption of PD-L1 testing in Europe using Germany and Italy as examples, to understand how different environments can generate different adoption rates, and look at how the process could be optimized.

Listen to the webinar to learn:

  • An overview of the pathology testing landscape in Germany and Italy
  • The current PD-L1 testing landscape in Germany and Italy
  • Market differences, gap analysis and possible scenarios

Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions

Dec 14, 2016 | Speakers: Ewelina Golebiewska, Steve Vitale, Ryan Keeling

For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make considered predictions for the industry as it develops.

Listen to the webinar to learn:

  • What’s new in this year’s Pharma Readiness for Dx report
  • How the diagnostic market is currently placed and where it is heading in 2017 and beyond
  • How pharma readiness and financial risks can impact the industry

How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights

Sep 20, 2016 | Speakers: Steve Vitale, Peter Keeling, Ryan Keeling

To date, multiple PD-L1 therapies have been launched – some with a diagnostic test in-label and some not. For those therapies that require testing, we will highlight how test adoption can be optimized.

Listen to the webinar to learn:

  • 10 years of personalized medicine evidence-based insights from Diaceutics
  • The latest in data and research on PD-L1 testing, adoptions, kits and labels
  • How to prepare for targeted therapy launches
  • Laboratory mapping and optimal lab footprints based on therapy, test and target prescribers

Personalized Medicine: What Are the Up and Coming Therapeutic Areas in Non-Oncology

Jun 21, 2016 | Speakers: Peter Keeling, Mark Reis, Steve Vitale

For the most part, personalized medicine and targeted therapies have been focused on oncology. However, there is new and exciting activity outside of oncology where biomarker and targeted approaches are proving successful.  This webinar provides insights on those non-oncology therapeutic areas to watch and the data available to support your your targeted therapy launch.

Listen to the webinar to learn:

  • The latest findings in non-oncology targeted therapies
  • How to prepare for targeted therapy launches
  • Competitive intelligence and market research data available for targeted therapy launches

To Test or Not To Test – Avoiding Costly Planning Mistakes with Effective Dx Financial Pre-Launch Planning

May 25, 2016 | Speakers: Peter Keeling, Mark Reis, Sanna Jousi

Are you at the pre-launch or commercial implementation stage of planning for a therapy and diagnostic? This webinar provides insights on how to optimize your therapy launch to maximize the therapy’s revenue opportunity.

Listen to the webinar to learn:

  • About effective financial planning for integrating diagnostics into your targeted therapy commercial strategy; and
  • That through optimization of the diagnostic, pharma can predict the revenue and patient share losses and gains that can be made in key markets and maximize the return on investment for the therapy asset.

The Value of Diagnostic Pre-Launch Planning for Targeted Therapies – Through the PD-L1 Lens

Apr 06, 2016 | Speakers: Peter Keeling, Sanna Jousi

Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics’ recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize your therapy revenue opportunity.

Listen to this webinar to learn:

  • that $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost; and
  • why ineffective diagnostic launch planning can lead to lost therapy revenue and how, with the proper planning tools, the maximum therapy opportunity can be achieved.

Global Laboratory Landscape Data and Strategy for Targeted Therapy Launches: Understanding CDx Intelligence and Trends

Feb 24, 2016 | Speakers: Ryan Keeling, Jordan Clark

Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch.

Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted therapy launches – the molecular laboratory.

Listen to this webinar to learn:

  • How the laboratory landscape and testing environment impacts therapy launches globally
  • Laboratory Mapping and optimal lab footprints based on a therapy, a test and target prescribers
  • The types of biomarker testing being done on a regional basis
  • Key testing measurement criteria about laboratories you need to know
  • Challenges and opportunities in developing regional lab networks to support quality testing

Personalized Medicine Forecast 2016

Jan 28, 2016 | Speakers: Steve Vitale, Peter Keeling, Mark Reis

A forecast for the industry raises some interesting points. Will there be 50 per cent more targeted therapy launches in 2016? Are labs becoming the key pharma launch partners? Are payer value models finally get some traction? And how will companion and complementary diagnostics be defined?

Listen to this webinar to learn:

  • Insights on the latest trends in targeted therapies
  • Best practices for your companion and complementary diagnostics launch
  • What you should be thinking about for your successful launch

Is Pharma Leveraging the Diagnostic in Targeted Therapy Branding and Communications?

Jun 01, 2015 | Speakers: Mark Reis, Sanna Jousi, Paul J Pfleiderer

Targeted therapy communications present a host of new opportunities and challenges for brand teams. Research has shown that positive diagnostic sentiment among consumers can be leveraged to enhance and optimize targeted therapy communications. But until now no reports have studied the communication styles pharma has used in targeted therapy communications.

This webinar, led by the Bioceutics team, provides an analysis of targeted therapy communications looking at pharma communication styles, positioning and strategies. It draws insight from the Bioceutics Personalized Healthcare Brand Index Surveillance Report, a first of its kind study of targeted therapies in the marketplace.

Listen to this webinar to learn:

  • An analysis of targeted therapy communications looking at communication styles, positioning and strategies
  • The key drivers in taking a particular communications path
  • What’s working and what’s not working
  • Real world examples and learnings

Global Laboratory Landscape Data for Targeted Pharma Therapy Launches: Are You Ready?

May 01, 2015 | Speakers: Mark Reis, Ryan Keeling, Jordan Clark

Will you be launching a targeted therapy in the next 24 to 48 months? This Labceutics webinar provides key insights into laboratory strategy, data and key market landscape differences when planning for a targeted therapy launch.

Join an expert panel of targeted therapy and laboratory data experts to hear about the ‘forgotten’ but critical stakeholder in successful global targeted therapy launches – the molecular laboratory.

Listen to this webinar to learn:

  • How the laboratory landscape and testing environment impacts therapy launches globally
  • Laboratory Mapping and optimal lab footprints based on a therapy, a test and target prescribers
  • The types of biomarker testing being done on a regional basis
  • Key testing measurement criteria about laboratories you need to know
  • Challenges and opportunities in developing regional lab networks to support quality testing

Diaceutics Personalized Medicine 2.0 – Integrating Key Learnings Across the Organization

Mar 25, 2014 | Speakers: Peter Keeling, Paul Tunnah, Scott Rairigh

This webinar focuses on personalized medicine education across the pharmaceutical company, from the R&D team to regulatory, and from commercial to public affairs, asking how can you ensure corporate knowledge and memory is where it needs to be to optimize personalized medicine strategies across the company.

Listen to this webinar to learn:

  • Why a strategic CDx strategy is essential to future pharma commercialization outside oncology
  • How to internally integrate personalized medicine design into the development and commercialization plan
  • Ways to educate global teams efficiently across the organization
  • The return on investment of early versus late planning outside oncology